Full Breakdown
Leadership Changes and New Initiatives at BDC Capital
11/19/2025, 4:56:59 PM
Overview of Recent Developments
The Business Development Bank of Canada (BDC) is undergoing significant changes as it prepares to launch a new Life Sciences Fund while reshaping its leadership team. This follows the departure of Dominique Bélanger, managing partner of BDC Capital’s Growth Venture Fund, just nine months after the fund received a substantial $1 billion allocation and an expanded mandate.
Leadership Transition and Fund Launch
Dominique Bélanger announced his departure from BDC Capital on November 7, 2023, stating that it was BDC’s decision to seek new leadership for the Growth Venture Fund. Bélanger had been with BDC for over 15 years, transforming the fund from an $80 million pilot to a nearly $1 billion growth fund. BDC is currently in the process of hiring a managing partner for the new Life Sciences Fund, which is set to launch in 2026. A spokesperson for BDC described the leadership change as part of a strategy to enhance operational efficiency and productivity.
Strategic Initiatives and Funding Allocations
BDC has been actively expanding its investment initiatives, including a $50 million search fund for women entrepreneurs, a $200 million second Industrial Innovation Venture Fund, and a $100 million commitment to rural entrepreneurs. Additionally, BDC is working on establishing a $100 million Black Entrepreneurs Fund and a $100 million Indigenous Entrepreneurship Fund. The new Life Sciences Fund aims to make early-stage investments in biotherapeutics and medical technology, with a focus on addressing unmet needs in the market.
Criticism and Industry Perspectives
The decision to launch another Life Sciences Fund has raised eyebrows among some Canadian venture capital sources, who questioned the rationale behind this move given the recent spinout of Amplitude Ventures. Critics argue that BDC should focus on supporting existing Canadian funds rather than creating new ones. However, BDC maintains that the new fund will target different stages of development and is informed by a third-party analysis of market gaps.
Peter van der Velden, founder of Lumira Ventures, acknowledged the new fund as a positive step but emphasized the need for more capital in the Canadian life sciences sector. He noted that many top Canadian life sciences companies will require significant funding in the coming years, which may not be readily available domestically.
Future Outlook
The Canadian Venture Capital & Private Equity Association (CVCA) has highlighted the strength of domestic life sciences investment, with nearly $1.07 billion deployed across 82 transactions in 2023. However, the trend of fewer, larger financings raises concerns about the overall health of the sector. Van der Velden warned that without adequate funding, many promising businesses may struggle to survive or may relocate to the United States.
Verbatim Quotes
- “It is time for someone else to take this to the next level,” — Dominique Bélanger, former Managing Partner, BDC Capital
- “We are grateful for what [Bélanger] has accomplished during his time at BDC, and steps are currently underway to ensure a smooth transition,” — BDC Spokesperson
- “ BDC said this fund “will not change” its commitment to indirect investment.” — BDC Spokesperson
- “This echoes his comments on LinkedIn yesterday, where he claimed every dollar deployed into Canadian life sciences startups at the early stage will require $20 of follow-on capital to succeed.” — Peter van der Velden, Founder, Lumira Ventures
The ongoing changes at BDC Capital reflect a broader strategy to enhance investment in the Canadian life sciences sector, despite the challenges and criticisms surrounding these initiatives.
